Cogent Biosciences, Inc. (COGT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$34.76-0.54%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · COGT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||
| Revenues | — | — | — | — | — | — | 7.9 | 22.5 | 9.7 |
| Operating Expenses & Income | |||||||||
| R&D Expenses | 290.7 | 269.8 | 232.7 | 173.8 | 121.6 | 55.9 | 25.7 | 43.7 | 38.3 |
| Operating Income | (389.1) | (333.4) | (275.9) | (208.1) | (147.8) | (75.6) | (82.2) | (32.2) | (36.0) |
| Earnings from Continuing Operations | |||||||||
| Interest Expense | — | 3.1 | — | — | — | — | — | — | — |
| Interest & Investment Income | 24.4 | 14.7 | 18.1 | 13.1 | 4.0 | 0.5 | 0.1 | 0.3 | 1.2 |
| Other Non-Operating Income / Expenses | 11.9 | 4.4 | 20.1 | 15.7 | 7.6 | 3.3 | 7.4 | 0.3 | 1.5 |
| Net Income | |||||||||
| Net Income | (377.2) | (328.9) | (255.9) | (192.4) | (140.2) | (72.3) | (74.8) | (31.8) | (34.5) |
| Per Share | |||||||||
| Basic EPS | (2.21) | (2.16) | (1.94) | (1.94) | (1.73) | (1.87) | — | — | — |
| Diluted EPS | (2.21) | (2.16) | (1.94) | (1.94) | (1.73) | (1.87) | — | — | — |
| Basic Weighted Avg Shares | 171.0 | 128.9 | 103.9 | 79.7 | 58.7 | 38.7 | — | — | — |
| Diluted Weighted Avg Shares | 171.0 | 128.9 | 103.9 | 79.7 | 58.7 | 38.7 | — | — | — |
| Supplemental | |||||||||
| EBITDA | — | (330.8) | (273.4) | (205.8) | (147.0) | (75.4) | (81.5) | (30.9) | (34.7) |
| EBIT | (389.1) | (333.4) | (275.9) | (208.1) | (147.8) | (75.6) | (82.2) | (32.2) | (36.0) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.